Lucid Diagnostics Inc.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

LUCD$0.42+4.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

· · Years Ended December 31, ·
· · 2025 · · · 2024 ·
Revenue	$4,706	$4,346
Operating expenses:
Cost of revenue	6,670	7,099
Sales and marketing	17,710	16,463
General and administrative	23,867	20,156
Amortization of acquired intangible assets	421	688
Research and development	5,678	5,992
Total operating expenses	54,346	50,398
Operating loss	(49,640)	(46,052)
Other income (expense):
Interest income	386	322
Interest expense	(22)	(26)
Change in fair value - Senior Secured Convertible Note	(7,656)	5,394
Debt extinguishments loss - Senior Secured Convertible Note	—	(5,167)
Equity issuance cost extinguishment	(1,078)	—
Other income (expense), net	(8,370)	523
Loss before provision for income tax	(58,010)	(45,529)
Provision for income taxes	—	—
Net loss attributable to Lucid Diagnostics Inc.	$(58,010)	$(45,529)
Less: Deemed dividend on Series A and Series A-1 Convertible Preferred Stock	—	(7,496)
Less: Series B and Series B-1 Convertible Preferred Stock dividends earned	(12,559)	—
Net loss attributable to Lucid Diagnostics Inc. common stockholders	$(70,569)	$(53,025)
Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - basic and diluted	$(0.69)	$(1.05)
Weighted average common shares outstanding, basic and diluted	101,946,871	50,515,773

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.